Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis
| Autor: | Dominique Baeten, Jacqueline E Paramarta, Leen De Rycke, Nataliya Yeremenko, M. Turina |
|---|---|
| Přispěvatelé: | Clinical Immunology and Rheumatology, AII - Amsterdam institute for Infection and Immunity, General Internal Medicine |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Immunology Enzyme-Linked Immunosorbent Assay Placebo Sensitivity and Specificity Gastroenterology Receptors Tumor Necrosis Factor Etanercept S100A8 Rheumatology Internal medicine medicine Humans Immunology and Allergy Spondylitis Ankylosing Ankylosing spondylitis business.industry Research Anti-Inflammatory Agents Non-Steroidal Antibodies Monoclonal medicine.disease Infliximab Immunoglobulin G Cohort Spondylarthropathies Calprotectin business Leukocyte L1 Antigen Complex Biomarkers medicine.drug |
| Zdroj: | Arthritis research & therapy, 16(4). BioMed Central Arthritis Research & Therapy |
| ISSN: | 1478-6354 |
| DOI: | 10.1186/s13075-014-0413-4 |
| Popis: | Introduction Biomarkers complementing clinical evaluations may help to reduce the length and size of proof-of-concept (PoC) trials aimed to obtain quick “go/no go” decisions in the clinical development of new treatments. We aimed to identify and validate serum biomarkers with a high sensitivity to change upon effective treatment in spondyloarthritis (SpA) PoC trials. Methods The candidate biomarkers high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), pentraxin-3 (PTX-3), alpha-2-macroglobulin (alpha-2-MG), matrix metalloproteinase-3 (MMP-3), calprotectin, and vascular endothelial growth factor (VEGF) were determined by enzyme-linked immunosorbent assay (ELISA) in healthy controls (n = 20) and SpA patients before and after 2 weeks of infliximab (n = 18) or placebo (n = 19) treatment in cohort 1. Clinical outcome was evaluated at week 12. Results were validated in ankylosing spondylitis (AS) with infliximab (cohort 2, n = 21) and peripheral SpA with etanercept (cohort 3, n = 20). Results Serum levels of calprotectin, hs-CRP, PTX-3, VEGF (all P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink